Bisoprolol Should Be Discontinued or Significantly Reduced in Symptomatic Bradycardia
In patients with symptomatic bradycardia (heart rate <60 bpm), bisoprolol should be stopped or dose-reduced rather than continued at any dose, as bradycardia <50 bpm is a contraindication to beta-blocker therapy.
Key Contraindication
The ESC Heart Failure Guidelines explicitly list sinus bradycardia (<50 bpm) as a Class I contraindication to beta-blocker therapy 1. This is not a relative contraindication—it is an absolute one when symptomatic.
Clinical Decision Algorithm
If Patient Has Heart Failure:
- Temporarily discontinue bisoprolol if severe symptoms present 1
- Re-institute at very low dose (1.25 mg once daily) only after clinical stabilization 1
- Do not up-titrate if pulse rate remains <50 bpm 1
- Consider switching from carvedilol to bisoprolol or metoprolol if already on carvedilol, as these may be better tolerated in bradycardia settings 2
If Patient Does NOT Have Heart Failure:
- Stop bisoprolol entirely 1
- Evaluate for reversible causes of bradycardia (medications, electrolytes, hypothyroidism)
- Consider permanent pacemaker if symptomatic bradycardia persists after drug withdrawal 3, 4
Dose Titration Guidance (When Restarting)
The FDA label and guidelines provide clear dose parameters 5:
- Starting dose: 1.25 mg once daily (not 2.5 mg or 5 mg)
- Titration: Only increase if heart rate remains >50 bpm and patient is asymptomatic
- Target: Aim for heart rate 55-70 bpm in heart failure patients 6, 2
- Maximum: Do not exceed 10 mg daily in most patients; 20 mg only for hypertension without bradycardia 5
Critical Pitfalls to Avoid
Do not continue bisoprolol at any dose if:
- Heart rate <50 bpm with symptoms (dizziness, syncope, fatigue) 1
- Second- or third-degree heart block present 1
- Sick sinus syndrome without pacemaker 1
Common error: Clinicians sometimes reduce the dose (e.g., from 5 mg to 2.5 mg) in symptomatic bradycardia. This is insufficient—the drug should be stopped entirely until heart rate normalizes, then restarted at 1.25 mg only if clinically indicated 1.
Special Populations
Renal/Hepatic Impairment:
If restarting bisoprolol after bradycardia resolution, use 2.5 mg starting dose (not 1.25 mg) in patients with creatinine clearance <40 mL/min or hepatic dysfunction 5.
Elderly Patients:
No dose adjustment needed unless concurrent renal/hepatic dysfunction, but monitor closely for bradycardia as elderly patients are more susceptible 5.
When Beta-Blockade Is Still Needed
If the patient requires beta-blockade for another indication (e.g., atrial fibrillation rate control, post-MI protection) but has developed symptomatic bradycardia:
- Stop bisoprolol immediately 1
- Address reversible causes (digoxin interaction, calcium channel blockers, electrolytes) 7
- Consider pacemaker placement if bradycardia persists and beta-blockade is essential 3, 4
- Only restart at 1.25 mg after pacemaker if needed 1
The 2018 ACC/AHA/HRS Bradycardia Guidelines emphasize that treatment decisions should focus on symptoms rather than arbitrary heart rate cutoffs, but rates <50 bpm with symptoms warrant immediate intervention 4, 8.